Salarius Pharmaceuticals (SLRX) Competitors $5.32 -0.12 (-2.21%) Closing price 04:00 PM EasternExtended Trading$5.28 -0.04 (-0.85%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock SLRX vs. GRI, NBY, VRAX, CERO, RDHL, QLGN, BIVI, ELAB, ENVB, and PWUPShould you be buying Salarius Pharmaceuticals stock or one of its competitors? The main competitors of Salarius Pharmaceuticals include GRI Bio (GRI), NovaBay Pharmaceuticals (NBY), Virax Biolabs Group (VRAX), CERo Therapeutics (CERO), Redhill Biopharma (RDHL), Qualigen Therapeutics (QLGN), BioVie (BIVI), PMGC (ELAB), Enveric Biosciences (ENVB), and PowerUp Acquisition (PWUP). These companies are all part of the "pharmaceutical products" industry. Salarius Pharmaceuticals vs. Its Competitors GRI Bio NovaBay Pharmaceuticals Virax Biolabs Group CERo Therapeutics Redhill Biopharma Qualigen Therapeutics BioVie PMGC Enveric Biosciences PowerUp Acquisition GRI Bio (NASDAQ:GRI) and Salarius Pharmaceuticals (NASDAQ:SLRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation. Does the media favor GRI or SLRX? In the previous week, Salarius Pharmaceuticals had 7 more articles in the media than GRI Bio. MarketBeat recorded 8 mentions for Salarius Pharmaceuticals and 1 mentions for GRI Bio. GRI Bio's average media sentiment score of 0.00 beat Salarius Pharmaceuticals' score of -0.38 indicating that GRI Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRI Bio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Salarius Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend GRI or SLRX? GRI Bio currently has a consensus target price of $22.00, suggesting a potential upside of 1,482.73%. Given GRI Bio's stronger consensus rating and higher possible upside, research analysts clearly believe GRI Bio is more favorable than Salarius Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GRI Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Salarius Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is GRI or SLRX more profitable? GRI Bio's return on equity of -327.62% beat Salarius Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets GRI BioN/A -327.62% -191.40% Salarius Pharmaceuticals N/A -556.47%-192.35% Do insiders and institutionals have more ownership in GRI or SLRX? 34.0% of GRI Bio shares are held by institutional investors. Comparatively, 11.9% of Salarius Pharmaceuticals shares are held by institutional investors. 0.9% of GRI Bio shares are held by insiders. Comparatively, 1.2% of Salarius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, GRI or SLRX? GRI Bio has a beta of -1.61, indicating that its stock price is 261% less volatile than the S&P 500. Comparatively, Salarius Pharmaceuticals has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Which has better earnings and valuation, GRI or SLRX? Salarius Pharmaceuticals is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGRI BioN/AN/A-$8.21M-$11.56-0.12Salarius PharmaceuticalsN/AN/A-$5.58M-$2.90-1.83 SummaryGRI Bio beats Salarius Pharmaceuticals on 8 of the 13 factors compared between the two stocks. Get Salarius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLRX vs. The Competition Export to ExcelMetricSalarius PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$745K$2.49B$5.74B$9.56BDividend YieldN/A1.66%4.53%4.07%P/E Ratio-0.1222.4730.4325.14Price / SalesN/A549.48392.4187.63Price / CashN/A173.7937.0358.50Price / Book-0.915.278.956.21Net Income-$5.58M$31.83M$3.26B$265.38M7 Day Performance-21.66%0.85%1.03%-1.12%1 Month Performance-51.15%3.72%4.28%-0.68%1 Year Performance-81.90%9.51%28.38%18.92% Salarius Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLRXSalarius Pharmaceuticals0.1308 of 5 stars$5.32-2.2%N/A-82.0%$745KN/A-0.1220Stock SplitGRIGRI Bio1.4963 of 5 stars$1.48+1.0%$22.00+1,382.1%-82.6%$3.74MN/A-0.131Earnings ReportShort Interest ↑NBYNovaBay Pharmaceuticals0.3846 of 5 stars$0.62-0.5%$0.85+37.1%+84.5%$3.61M$9.78M-0.0130News CoverageVRAXVirax Biolabs Group3.2262 of 5 stars$0.780.0%$3.00+283.1%-78.7%$3.40M$10K0.005Positive NewsShort Interest ↓CEROCERo Therapeutics2.8652 of 5 stars$8.74-0.7%$45.00+414.9%-96.9%$3.40MN/A0.008RDHLRedhill BiopharmaN/A$1.44-0.3%N/A-84.7%$3.30M$8.04M0.00210News CoverageGap DownQLGNQualigen TherapeuticsN/A$1.94+2.1%N/A-81.5%$3.18M$4.98M0.0050Earnings ReportGap UpBIVIBioVie0.3733 of 5 stars$1.70-2.9%N/A-95.3%$3.16MN/A-0.0210ELABPMGC0.7033 of 5 stars$1.99+0.5%N/A-99.5%$2.95M$1.71M0.0018ENVBEnveric Biosciences2.2721 of 5 stars$1.16-2.5%$10.00+762.1%-86.7%$2.87MN/A-0.0320Positive NewsEarnings ReportPWUPPowerUp AcquisitionN/A$0.36-7.8%N/A-95.8%$2.79MN/A0.00N/AHigh Trading Volume Related Companies and Tools Related Companies GRI Competitors NBY Competitors VRAX Competitors CERO Competitors RDHL Competitors QLGN Competitors BIVI Competitors ELAB Competitors ENVB Competitors PWUP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLRX) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Salarius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access